fbpx
Contact Us

Open Clinical Trials at Colorado Clinical Research

 

Amplitude

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC).

Capitello 280

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC).

Capitello 281

A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281).

Merck

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle invasive Bladder Cancer (HR NMIBC) that is either Persistent or Recurrent Following BCG Induction or that is Naïve to BCG Treatment (KEYNOTE-676).

Proteus

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy.

Sunrise 1

“Phase 2b Clinical Study Evaluating Efficacy and Safety of TAR-200 in Combination with Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin (BCG) who are Ineligible for or Elected Not to Undergo Radical Cystectomy.

Sunrise 2

A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder who are not Receiving Radical Cystectomy”.

VERACITY

Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Prior Treatment with at Least One Androgen Receptor Targeting Agent.

Zenith

Randomized Phase 2b Study of ZEN003694 in Combination with Enzalutamide versus Enzalutamide Monotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer.

ZenFlow

Safety and Effectiveness Study of the Zenflow Spring System – A Minimally Invasive Treatment for LUTS associated with BPH (BREEZE).

We’re here to help- Call Colorado Clinical Research for more information about our open clinical trials – 303-996-9649. 

Contact Us

Appointments & Information

*If this is an emergency, please call 911 immediately.

Please provide your email address and phone number and a Colorado Urology representative will contact you shortly to assist with your question or issue.

Monday–Friday, 8:30 a.m. to 4:30 p.m.

  • This field is for validation purposes and should be left unchanged.

Contact Us